A solid form (A) of an anti-EGFR (epidermal growth factor receptor) antibody (Ab) and/or its variants and/or fragments, that, when dissolved or suspended in aqueous medium generates biologically active Ab protein, is new, where (A) is prepared by precipitation of Ab, dissolving or suspending in aqueous medium, using a precipitation agent (B), optionally followed by separating the precipitate. ACTIVITY : Cytostatic； Antidiabetic； Ophthalmological； Antiinflammatory； Antipsoriatic； Antirheumatic； Antiarthritic； Vulnerary； Immunosuppressive； Immunostimulator； Vasotropic. No details of tests for these activities are given. MECHANISM OF ACTION : Inhibiting binding of ligands (specifically epidermal growth factor) to EGFR and inhibiting EGFR-mediated signal transduction, resulting in inhibition of cell proliferation； Reduction in tumor-associated angiogenesis； Induction of apoptosis and increased effects for radiation and chemical therapy.
